# Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

> **NCT06767956** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Pittsburgh**

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** GOLCADOMIDE
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06767956
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND Sponsor-Investigator left institution
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767956, "Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06767956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*